An open-label, multi-centre, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
The ANTICOV study aims to identify one or two treatments that could be used to treat mild and moderate cases of COVID-19, to stop the disease from getting more serious. The goal of the study is to find a treatment to help avoid mass hospitalizations in African health systems with limited intensive care facilities. If successful, it will also have important implications for other regions.
Primary objective: The primary objective is to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease
Type of study: Interventional; Phase III, treatment
Treatment tested: Antimalarials, antivirals
Countries: Burkina Faso, Cameroon, the Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Ghana, Guinea, Ivory Coast, Kenya, Mali, Mozambique, Niger, Sudan, and Uganda
Sample size: Between 2000 and 3000 patients
Study participants: Adults over 18 years with mild or moderate COVID-19
Study status: Not yet recruiting (as of 30 June 2020)
- Dr Nathalie Strub-Wourgaft: email@example.com
- Study ID: PACTR202006537901307
- Trial registry: Pan African Clinical trials Registry (PACTR)
Last updated: August 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.